Related Experiment Video

Updated: Jun 28, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Trastuzumab: mechanisms of resistance and therapeutic opportunities

Aknar Calabrich1, Gustavo Dos Santos Fernandes, Artur Katz

  • 1Oncology Center, Hospital Sirio-Libanes, São Paulo, Brazil.

Oncology (Williston Park, N.Y.)
|November 5, 2008
PubMed

Insights

Many HER2-positive breast cancer patients do not respond to trastuzumab (Herceptin) therapy or develop resistance. This review explores molecular mechanisms like PTEN loss and alternative pathways, suggesting therapeutic targets to overcome resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • HER2 overexpression is common in breast cancer.
  • Trastuzumab (Herceptin) is a targeted therapy for HER2-positive breast cancer.
  • Many patients exhibit primary or acquired resistance to trastuzumab.

Purpose of the Study:

  • To review molecular mechanisms underlying trastuzumab resistance in HER2-positive breast cancer.
  • To identify potential therapeutic targets for overcoming trastuzumab resistance.

Main Methods:

  • Literature review of molecular mechanisms of trastuzumab resistance.
  • Analysis of signaling pathways and genetic alterations.
  • Discussion of potential therapeutic strategies.

Main Results:

  • Key resistance mechanisms include PTEN loss, activation of alternative signaling pathways (e.g., HER3, IGF-1R), and alterations in receptor-antibody interactions.
  • Circulating HER2 extracellular domain can also contribute to resistance.
  • These molecular aberrations represent potential targets for novel therapeutic interventions.

Conclusions:

  • Understanding the molecular basis of trastuzumab resistance is crucial for improving patient outcomes.
  • Targeting specific resistance mechanisms offers a promising strategy to overcome or prevent trastuzumab resistance in breast cancer patients.
  • Further research into these therapeutic targets may lead to more effective treatment regimens.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.